CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pandion Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pandion Therapeutics Inc
134 Coolidge Avenue, 2Nd Floor
Phone: (617) 393-5925p:617 393-5925 Watertown, MA  02472  United States
This company was Merged or Acquired on 4/1/2021.
This company ceased filing statements with the SEC on 4/12/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Pandion Therapeutics, Inc., formerly Pandion Therapeutics Holdco LLC, is a clinical-stage biopharmaceutical company. The Company is focused on developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. It is developing its Therapeutic Autoimmune reguLatOry protein (TALON) drug design and discovery platform. Its lead product candidate, PT101, a combination of its interleukin-2 (IL-2), mutein effector module with a protein backbone, is designed to selectively expand regulatory Treg cells, without activating proinflammatory cells, such as conventional T cells and natural killer (NK cells).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202012/31/2020YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Scientific Officer JoanneViney 54 7/1/2019 4/1/2017
President, Director Rita A.Karachun 56 4/1/2021 4/1/2021
Chief Executive Officer RahulKakkar 45 4/1/2021 8/1/2019
7 additional Officers and Directors records available in full report.

Business Names
Business Name
PAND
Pandion Operations, Inc.
Pandion ProgramCo 1, Inc.
Pandion Securities Corp.

General Information
Number of Employees: 56 (As of 12/31/2020)
Outstanding Shares: 29,515,583 (As of 3/12/2021)
Shareholders: 87
Stock Exchange: NASD
Federal Tax Id: 833015614


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023